Sarepta has a long and controversial history of getting its Duchenne drugs OK’d via accelerated approval. Now it will try in more rare diseases.

"We will apply that same focus and creative energy and patient-mission approach to these therapies," CEO Doug Ingram said.

https://endpts.com/sarepta-arrowhead-take-a-big-swing-on-sirna-drugs-for-rare-disease/